DelveInsight’s ’Vulvovaginal Candidiasis - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Vulvovaginal Candidiasis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Vulvovaginal Candidiasis from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan



Study Period: 2016-2027
Vulvovaginal Candidiasis - Disease Understanding and Treatment Algorithm
Vulvovaginal candidiasis (VVC) is an infection caused by Candida species that affects millions of women every year. The development of VVC is usually attributed to the disturbance of the balance between Candida vaginal colonization and host environment by physiological or non-physiological changes.
The DelveInsight Vulvovaginal Candidiasis market report gives the thorough understanding of the Vulvovaginal Candidiasis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Vulvovaginal Candidiasis in the US, Europe, and Japan.

Vulvovaginal Candidiasis Epidemiology
The Vulvovaginal Candidiasis epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Prevalent Cases, Age Specific Prevalence, and other sub-segmentation type] scenario of Vulvovaginal Candidiasis in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to Centers for Disease Control and Prevention (CDC), Vulvovaginal Candidiasis is the second most common type of vaginal infection after bacterial vaginal infections in the United States. Approximately 75.0% of all women aged 18 to 85 years (mean 32.0 years) in a study of vaginitis in a family practice clinic reported at least episode of VVC in their lives.

Vulvovaginal Candidiasis Drug Chapters
This segment of the Vulvovaginal Candidiasis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The current availability of over-the-counter (OTC) medications for Vulvovaginal candidiasis (VVC) is a convenient option for many women, although the accuracy of self-diagnosis is questionable. There are variety of effective treatments that include topical or oral antifungals. Currently available options for the treatment of this condition include antifungal intravaginal agents such as butoconazole, clotrimazole, miconazole, and tioconazole, available as OTC. Already approved antifungal agent, Diflucan (Pfizer) is being administered as a single dose oral medication for treatment of uncomplicated yeast infection.

Vulvovaginal Candidiasis Market Outlook
The Vulvovaginal Candidiasis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Emerging therapies such as Candiplus (Profem), MAT2203 (Matinus Biopharma), NDV-3A (NovaDigm Therapeutics), VT-1161 (Viamet Pharmaceuticals) and other compelling treatments, are expected to impact the market size of Vulvovaginal Candidiasis in upcoming years.

Vulvovaginal Candidiasis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
?
Vulvovaginal Candidiasis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies



Vulvovaginal Candidiasis Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Sub-type Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake



Vulvovaginal Candidiasis Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers




Key benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Vulvovaginal Candidiasis market
  • Organize sales and marketing efforts by identifying the best opportunities for Vulvovaginal Candidiasis market
  • To understand the future market competition in the Vulvovaginal Candidiasis market.